Loading stock data…
PBYI
$7.05+0.20 (+2.92%)
After Hours$7.05+0.00 (+0.00%)· Last close Jun 9
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Puma Biotechnology, Inc. in the Healthcare sector is trading at $7.05 with a market capitalization of $347M. Wall Street consensus targets $5.00 (1 analysts), implying a -29.1% move over the next 12 months. The stock is currently near its 52-week high of $7.90, remaining 16.5% above its 200-day moving average. On fundamentals, Piotroski 6/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 65/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply -29.1% downside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$7.05
Potential Downside
12.5%
Whystock Fair Value$6.17
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. It offers NERLYNX, an oral version of neratinib that is used to treat...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$346.63M
P/E Ratio
Value territory. Trading at a high yield relative to earnings.
14.19
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.23
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
18.99%
Volume
Today's trading volume
160,484
Recent News
Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings
Investors were disappointed with the weak earnings posted by Puma Biotechnology, Inc. ( NASDAQ:PBYI ). Despite the soft...
Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00
Puma Biotechnology, Inc. ( NASDAQ:PBYI ) just released its latest quarterly results and things are looking bullish...
Puma (PBYI) Q1 2026 Earnings Call Transcript
After the close today, Puma issued a news release detailing results for the first quarter of 2026. Today's conference call will include statements about Puma's future expectations, plans and prospects that constitute forward-looking statements for purposes of federal securities laws.
Puma Biotechnology Q1 Earnings Call Highlights
Puma Biotechnology (NASDAQ:PBYI) reported first-quarter 2026 total revenue of $44.8 million, driven primarily by NERLYNX product revenue net of $42.0 million and royalty revenue of $2.8 million, according to remarks on the company’s earnings call. Management attributed the quarter’s product revenue
PBYI Q1 Earnings & Sales Beat Estimates, 2026 Guidance Raised
Puma Biotechnology beats Q1 earnings and revenue estimates while raising its 2026 outlook.